for example, in alcoholism, depression, bipolar disorder, or Alzheimer’s disease (e.g., Ford, 1999). Still, P3 reductions and other neurophysiologic deficits have also been observed in unaffected relatives and first-episode patients (e.g., Bramon et al., 2005; Ford, 1999; Hirayasu et al., 1998; Michie, 2001; Turetsky et al., 2000; van der Stelt et al., 2005; Winterer et al., 2003), suggesting that certain electrophysiologic measures may be candidate risk biomarkers that may identify individuals at risk for schizophrenia (e.g., Luck et al., 2011).